Diltiazem Hydrochloride

Phase 3Small molecule

Diltiazem Hydrochloride is one of 72 small molecule programs targeting Pulmonary Arterial Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary Arterial HypertensionActive, not recruiting

Coronary Microvascular DysfunctionActive, not recruiting

Intestinal CancerNot yet recruiting

Pulmonary Arterial HypertensionPreclinical

Active, not recruiting

Coronary Microvascular DysfunctionPhase 3

Active, not recruiting

Intestinal CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

53 competitors in Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Letairis

Gilead

Approved

17 2

Tracleer

Johnson & Johnson

Approved

16 3

Winrevair

Merck & Co.

Approved

16 4

Opsumit

Johnson & Johnson

Approved

11 5

Remodulin

United Therapeutics

Approved

10 6

Uptravi

Johnson & Johnson

Approved

9 7

Cialis

Eli Lilly

Approved

9 8

Adempas

Bayer

Approved

7 9

Viagra

VViatris Specialty LLC

Aldactone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Coronary Microvascular Dysfunction

NCT04777045

Q1 2030

Phase 1/2Not yet recruiting

Intestinal Cancer

NCT07456852

Clinical

Trials by Indication[1]

Pulmonary Arterial Hypertension1 trial

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

Withdrawn·UUniversity of South Florida·N/A·NCT01645826

Coronary Microvascular Dysfunction1 trial

Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial

Active, not recruiting·RRadboud University Medical Center·Phase 3·NCT04777045·85 enrolled

Intestinal Cancer1 trial

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Not yet recruiting·MMayo Clinic·Phase 1/2·NCT07456852·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Diltiazem Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diltiazem Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diltiazem Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of South Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of South Florida

Diltiazem Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2030

Trials by Indication[1]

Pulmonary Arterial Hypertension1 trial

Coronary Microvascular Dysfunction1 trial

Intestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News